Tixagevimab/AZD8895 represents a unique medicinal method utilizing two monoclonal immunoglobulins. Specifically, these medications operate by specifically attaching to the spike area of the SARS-CoV-2 virus, hindering https://www.targetmol.com/compound/tixagevimab